Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-18

FDA Approved: ACIPHEX — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for ACIPHEX (rabeprazole sodium) submitted by Waylis Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ACIPHEX (rabeprazole sodium)

Snippet

SUPPL AP for ACIPHEX (RABEPRAZOLE SODIUM)